Compare RYOJ & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYOJ | MURA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Japan | Ireland |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 36.0M |
| IPO Year | 2025 | N/A |
| Metric | RYOJ | MURA |
|---|---|---|
| Price | $4.03 | $2.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 71.7K | ★ 224.8K |
| Earning Date | 12-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.91 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $11,576,848.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.25 | ★ N/A |
| Revenue Growth | ★ 5.60 | N/A |
| 52 Week Low | $1.81 | $0.95 |
| 52 Week High | $11.43 | $4.74 |
| Indicator | RYOJ | MURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.39 |
| Support Level | N/A | $2.06 |
| Resistance Level | N/A | $2.10 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 25.00 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.